Treatment results of breast sarcomas in national medical research center of oncology named after N.N. Blokhin
Abstract
Breast sarcomas (BS) are the group of rare malignant tumors of the breast, the optimal treatment is still under discussion. Patients and methods. We retrospectively reviewed 51 patients with BS between 1999 and 2017 in National Medical Research Center of Oncology named after N.N. Blokhin. Results. Five-year recurrence-free survival and OS rate were 37,5 and 56,2%, respectively. With median follow-up of 86,4 months, 43,14% patients (22/51) were found with local recurrence and metastasis. Conclusion. Disease stage and local recurrence were indicated as unfavorable prognostic factors. Surgery remains crucial treatment for breast sarcomas. Mastectomy is not routinely necessary if clear margin could be achieved by local excision. The combined approach is necessary in the treatment of high-grade sarcomas, taking into account the morphological and immunohistochemical parameters of the tumor.
About the Authors
S. V. Sopromadze
FGBU «National Medical Research Center of Oncology named after N.N. Blokhin» of the Ministry of Healthcare of the Russian Federation; Federal State Budgetary Educational Institution of Higher Education «A.I. Yevdokimov Moscow State University of Medicine and Dentistry» of the Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
V. A. Sobolevsky
FGBU «National Medical Research Center of Oncology named after N.N. Blokhin» of the Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
O. V. Krokhina
FGBU «National Medical Research Center of Oncology named after N.N. Blokhin» of the Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
A. A. Fedenko
FGBU «National Medical Research Center of Oncology named after N.N. Blokhin» of the Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
References
1. Yin M et al. Primary female breast sarcoma: clinicopathological features, treatment and prognosis. Sci Rep. 2016;6:31497. DOI: 10.1038/srep31497.
2. Moore MP, Kinne DW Breast sarcoma. Surg Clin North Am. 1996;76:383-92. DOI: 10.1016/S0039-6109(05)70445-X.
3. Kattan MW, Leung DH, Brennan MF. Postoperative nomogram for 12-year sarcoma-specific death. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2002;20:791-796.
4. Zelek L et al. Prognostic factors in primary breast sarcomas: a series of patients with long-term follow-up. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2003;21:2583-2588. DOI: 10.1200/ JCO.2003.06.080.
5. Li N et al. Breast sarcoma. A case report and review of literature. Int J Surg Case Rep. 2016;24:203-205.
6. Hefny AF et al. Stromal sarcoma of the breast: a case report. Asian J Surg. 2004;27:339-341.
7. McGowan TS et al. An analysis of 78 breast sarcoma patients without distant metastases at presentation. International journal of radiation oncology, biology, physics. 2000;46:383-390.
8. Holm M et al. Primary breast sarcoma: a retrospective study over 35 years from a single institution. Acta Oncol. 2016;55:584-590.
9. Rashmi Chugh M et al. Breast sarcoma: treatment. UpTo-Date, Waltham, 2016, http://www.uptodate.com/contents/ breast-sarcoma-treatment.
10. Hsu C, McCloskey SA, Peddi PF. Management of breast sarcoma. Surg Clin North Am. 2016;96:1047-1058.
11. Harris JR, Lippman ME, Morrow M, Osborne CK, editors. Diseases of the Breast. Ed 4. Philadelphia: Lippincott Williams & Wilkins. 2010:800-802.
12. Testori A et al. Huge malignant phyllodes breast tumor: a real entity in a new era of early breast cancer. World J Surg Oncol. 2015;13:81.
13. Blanchard DK, Reynolds CA, Grant CS, Donohue JH. Primary nonphylloides breast sarcomas. American journal of surgery. 2003;186:359-361.
14. Al-Benna S, Poggemann K, Steinau HU, Steinstraesser L. Diagnosis and management of primary breast sarcoma. Breast Cancer Res Treat. 2010;122(3):619-626. DOI: 10.1007/ s10549-010-0915-y.
15. Voutsadakis IA, Zaman K, Leyvraz S. Breast sarcomas: current and future perspectives. Breast. 2011;20:199-204.
16. Nizri E, Merimsky O, Lahat G. Optimal management of sarcomas of the breast: an update. Expert Rev Anticancer Ther. 2014;14(6):705-710. DOI: 10.1586/14737140.2014.895667.
17. Wang F, Jia X Tong Z. Comparison of the clinical and prognostic features of primary breast sarcomas and malignant phyllodes tumor. Jpn J Clin Oncol. 2015;45:146-152.
18. Воротников ИК. Листовидные опухоли и саркомы молочных желез: клиника, диагностика, лечение. Маммология. 1999;1:29-34.
19. Феденко АА. Модификация режимов химиотерапии сарком мягких тканей. Старые препараты и новые возможности. Саркомы костей, мягких тканей и опухоли кожи. 2015;(4):3-20.
20. Феденко АА, Конев АА, Анурова ОА и соавт. Ангиосаркомы. Саркомы костей, мягких тканей и опухоли кожи. 2013;(1):24-41.
21. Алиев МД, Бохян БЮ, Буров ДА. Прогностическая роль края резекции в хирургии сарком мягких тканей. Практическая онкология. 2013;14(2):97-100.
Review
For citations:
Sopromadze S.V., Sobolevsky V.A., Krokhina O.V., Fedenko A.A. Treatment results of breast sarcomas in national medical research center of oncology named after N.N. Blokhin. Bone and soft tissue sarcomas, tumors of the skin. 2018;10(2):43-48. (In Russ.)
Views:
184
Email this article 
